Registered outcomes27

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

21 to 27 of 27

List	Outcome	Time frame
Secondary	PFS as evaluated by the investigator according to HCC mRECIST	Approximately 2 years
Secondary	TTR as evaluated by the investigator according to HCC mRECIST	Approximately 2 years
Secondary	TTP as evaluated by the investigator according to HCC mRECIST	Approximately 2 years
Secondary	DCR as evaluated by the investigator according to HCC mRECIST	Approximately 2 years
Secondary	Overall survival (OS)	Approximately 3 years
Secondary	Safety and tolerability (any Advense Events (AEs), Severe AEs , immune-related AEs (irAEs), treatment-related AEs, abnormal laboratory values, etc.	Approximately 2 years
Secondary	Presence of Anti-Drug Antibodies (ADAs) to GT90001 and Nivolumab during the study relative to the presence of ADAs at baseline	Approximately 2 years

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT05178043/registered?page=2